US$34 million in emergency financing will provide access to vaccines for over 2 million people in Lebanon
As scientists try to track the spread of a new, more infectious coronavirus variant around the world — finding more cases in the United States and elsewhere this week — they are also keeping an eye on a different mutation with potentially greater implications for how well Covid-19 vaccines work.
National Institutes of Health researchers have isolated a set of promising, tiny antibodies, or “nanobodies,” against SARS-CoV-2 that were produced by a llama named Cormac.
Pregnant women who are infected with SARS-CoV-2, the virus that causes COVID-19, during the third trimester are unlikely to pass the infection to their newborns, suggests a study funded by the National Institutes of Health.
The huge vaccine reservoir means that COVAX, a 190-country international initiative that seeks to ensure all countries have equal access to coronavirus vaccines, can plan to start delivering the shots in the first quarter of 2021
In the pandemic’s first year, the work of ending the pandemic was confined to a relatively small domain: Labs and clinical trials
The U.S. Food and Drug Administration issued an Emergency Use Authorization (EUA) to Moderna, Inc., a biotechnology company based in Cambridge, Massachusetts, for its COVID-19 vaccine, which was co-developed with scientists at the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID).